Seres Therapeutics, Inc. (MCRB)

Market Cap	124.28M
Revenue (ttm)	n/a
Net Income (ttm)	136,000
Shares Out	174.36M
EPS (ttm)	0.00
PE Ratio	814.63
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	615,814
Open	0.702
Previous Close	0.713
Day's Range	0.700 - 0.720
52-Week Range	0.540 - 1.530
Beta	2.17
Analysts	Hold
Price Target	4.00 (+461.17%)
Earnings Date	Mar 13, 2025

About MCRB

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 26, 2015
• Employees: 103
• Stock Exchange: NASDAQ
• Ticker Symbol: MCRB
• Website: https://www.serestherapeutics.com

Analyst Forecast

According to 5 analysts, the average rating for MCRB stock is "Hold." The 12-month stock price forecast is $4.0, which is an increase of 461.17% from the latest price.

Price Target

$4.0

(461.17% upside)

Analyst Consensus: Hold